The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Emergent therapeutic strategies in the field of myeloproliferative malignancies
Claire Harrison, MD, DM, FRCP, FRCPath, from Guys and St Thomas’ NHS Foundation Trust, London, UK provides a general overview on emergent therapies in myeloproliferative malignancies. She talks about understanding molecular features of the disease in more depth in order to better target drugs. Prof Harrison provides a great outline of new data on therapies being generated around the world. She also provides insight into how one might go about devising treatment strategies that are tailored to the individual patient for e.g. molecular disease status. Lastly, she discusses emergent therapies for the rarer myeloproliferative malignancies which have shown promising results.
